Researchers have shown that adjuvant radiation therapy rather than salvage radiation therapy may improve the function of artificial urinary sphincters for stress...
Adding the phosphatidylserine-targeting antibody bavituximab to the immunotherapy agent pembrolizumab may improve response rates...
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, FASCO, and colleagues, the third prespecified interim analysis of overall survival...
In an analysis of patient-reported outcomes (PROs) in the DESTINY-Breast02 trial published in The Lancet Oncology, Tanja Fehm, MD, and colleagues found that general...
In patients with ovarian cancer, second-look surgery may find a role again. The evaluation of measurable residual disease (MRD) using second-look laparoscopy...
Cancer is not an unfamiliar disease to me. My mother died of cancer when I was 12. My oldest sister died of breast cancer, an aunt died of cancer (I don’t know which type), and my older brother is a prostate cancer survivor. So, when I was diagnosed with prostate cancer in October 2021, the news...
As reported in the Journal of Clinical Oncology by Sayan et al, analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy (WPRT) was associated with favorable survival outcomes vs prostate-only radiation therapy (PORT)...
On October 31, 2023, pembrolizumab (Keytruda) was approved for use with gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on the double-blind KEYNOTE-966 trial...
The National Institutes of Health (NIH) has launched the Cancer Screening Research Network, a clinical trials network to evaluate emerging cancer screening technologies. The new network will support the Biden-Harris Administration’s Cancer Moonshot initiative by investigating how to identify cancer ...
In a single-institution study reported in the Journal of Clinical Oncology, Watson et al identified risk factors for osteoradionecrosis of the jaw and developed a classification system for the condition in patients receiving radiation therapy for head and neck cancer. Study Details The study...
On December 1, 2023, pirtobrutinib (Jaypirca), a selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor that inhibits both wild-type and C481-mutant BTK with equal low nanomolar potency and is designed to address several of the limitations of covalent BTK inhibitors, was granted...
In an analysis of data from the PORTEC-1, -2, and -3 trials reported in The Lancet Oncology, Wakkerman et al found that older age was associated with more aggressive tumor features and poorer outcomes in patients with endometrial cancer. Study Details The analysis included data from 1,801...